心血管保健中的药物基因组学和风险分层:随机对照试验的见解
Sajjad Ahmed Khan1, Sadab Khan2, Huma Kausar2
1Birat Medical College Teaching Hospital, Morang, Nepal.
Medicine
|June 17, 2025
概括
基因组学和个性化医学正在彻底改变心脏病学. 遗传洞察力可以改善心血管疾病 (CVD) 风险评估,诊断和治疗,从而改善患者的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 基因组学就是基因组学.
- 个性化医疗是个性化的医疗.
背景情况:
- 心血管疾病 (CVD) 构成了严重的健康负担.
- 基因组学和个性化医学为心血管疾病管理提供了新的方法.
- 了解遗传因素是定制治疗的关键.
研究的目的:
- 审查基因型导向疗法,药物基因组学和心脏病学个性化医学的随机临床试验 (RCT).
- 分析遗传洞察对心脏病风险评估,诊断和治疗疗效的影响.
- 探索将基因组方法整合到心血管护理中的临床影响和挑战.
主要方法:
- 对精选的RCT进行叙述性审查,重点关注心血管疾病的遗传因素.
- 对药物基因组数据和个性化治疗策略的研究分析.
- 评估遗传关联,治疗疗效和临床结果.
主要成果:
- 鉴定与心血管疾病风险增加相关的遗传变异,并制定基因组风险评分.
- 发现影响心血管药物反应和疗效的遗传决定因素.
- 支持基因测试指导抗血小板治疗,优化药物剂量和减少不良影响的证据.
结论:
- 基因组学和个性化医学具有改变心血管保健的巨大潜力.
- 基因检测可以提高心脏病学中的治疗选择,疗效和安全性.
- 克服实施挑战,成本效益和道德问题对于广泛采用至关重要.
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
184
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
184
Cardiovascular Drugs: Classification based on Therapeutic Indications
3.2K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.2K
Factors Affecting Drug Response: Overview
2.4K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.4K
Atherosclerosis III: Management
42
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
42
Analysis of Population Pharmacokinetic Data
397
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
397
Genome-wide Association Studies-GWAS
14.4K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
14.4K


